Quest PharmaTech Inc.
QPT.V
TSX
| 01/31/2025 | 10/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 18.39% | 19.86% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.51% | 36.97% | |||
| Operating Income | -8.51% | -36.97% | |||
| Income Before Tax | -4,793.31% | -95.17% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -4,793.31% | -95.17% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -4,793.31% | -95.17% | |||
| EBIT | -8.51% | -36.97% | |||
| EBITDA | -8.60% | -37.03% | |||
| EPS Basic | -3,600.00% | -93.55% | |||
| Normalized Basic EPS | -128.57% | -177.78% | |||
| EPS Diluted | -3,600.00% | -93.55% | |||
| Normalized Diluted EPS | -128.57% | -177.78% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||